Whatsmore, CD200 has been shown to promote immunosuppression in the pancreatic tumor microenvironment and targeting CD200 may enhance activity of checkpoint immunotherapy (Choueiry et al., 2020). This evidence concerns the gene CD200 and pancreatic neoplasm.